DPP-4 inhibitors thus affect glucose regulation by augmenting the incretin system
Please note that when a status is noted as "available," this reflects the most current information from the manufacturer but is not an FDA determination that the shortage has been resolved
Given their antiinflammatory properties, there has been some speculation that GLP-1 medicines could impair host immune defenses, but current clinical evidence does not indicate an increased risk of infections or obesity-related cancer (94)
Adipose overexpression of desnutrin promotes fatty acid use and attenuates diet-induced obesity
Recent clinical wins include: Taltz + Zepbound combination: Delivered superior efficacy in adults with psoriatic arthritis and obesity Orforglipron: Helped patients maintain weight loss after switching from injectables to oral therapy a potentially massive market expansion Retatrutide: The companys triple agonist delivered average weight loss of 71.2 pounds along with substantial osteoarthritis pain relief The orforglipron data matters particularly for the competitive landscape
These average results increased at higher doses: about 17.1% at the 4 mg dose, 22.8% at the 8 mg dose, and 24.2% at the 12 mg dose